The Beacon
Kanal-Details
The Beacon
Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.
Neueste Episoden
75 Episoden
Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)
Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the evidence on an optimal duration of immunotherapy for long-respondi...
Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)
Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the challenges of conducting clinical trials and delivering increasing...
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter.
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard chemotherapy for r...
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for advanced non-squam...
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic advance...
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
Dr. Jack West reviews the IMpower132 trial of platinum + pemetrexed with or without atezolizumab as first line treatment for advanced non-squamous NSC...
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what we know about results, and th...
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with advanced NSCLC perform...
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line therapy for ad...
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage III N...
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses whether the resul...
"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)
Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer are best served by receiving th...
Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)
Dr. Jack West reviews general principles for how local therapies are increasingly appropriate for selected patients with advanced NSCLC, whether at in...
TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)
Dr. Dan Goldstein reviews results of a trial of chemo regimen TIP (paclitaxel, ifosfamide, cisplatin) vs BEP (bleomycin, etoposide, cisplatin) for int...
Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)
Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Lehtinen, assessing the benefit of adjuvant docetaxel for...
What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)
Dr. Daniel Goldstein reviews data on the positive predictive value of PET PSMA imaging in patients with biochemically relapsed prostate cancer, as pre...
New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone for molecularly unsele...
Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)
Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the implications of trials...
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonged duration of radium-223 (Xofi...
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic pr...
Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic k...
Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients with metastatic clear...
Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)
Dr. Daniel Goldstein summarizes the findings of a randomized trial assessing the benefit of adjuvant sunitinib following resection of oligometastatic...
Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051)
Dr. Daniel Goldstein reviews the key data and limitations from the CARMENA trial that re-evaluated the role of nephrectomy in metastatic renal cell ca...
Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including the novel agent erdafitinib as a treatment targeting fibroblast gr...
Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)
Dr. Daniel Goldstein reviews provocative and highly promising results with enfortumab, an inhibitor of nectin-4, as a treatment for advanced transitio...
Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (BMIC-048)
Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these...
Could Immunotherapy Replace Neoadjuvant Chemo for Muscle-Invasive Transitional Cell Carcinoma? Highlights from ASCO 2018 (BMIC-047)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunothe...
How do Patients with Advanced NSCLC on Daily Steroids Do on Immune Checkpoint Inhibitors? (BMIC-046)
Dr. Jack West summarizes findings of a retrospective analysis from Dr. Arbour of MSKCC, evaluating the clinical outcomes of patients with advanced NSC...
Is Chemo the Key to the Best Combination for EGFR Mutation-Positive NSCLC? The Data Too Good to Overlook (BMIC-045)
Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as initial thera...
Is the Survival Benefit from Dacomitinib on the ARCHER-1050 Trial Enough to Make it a Contender as First Line Treatment for EGFR Mutation-Positive NSCLC Today? (BMIC-044)
Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR mutation-positive NSCLC, asks whether the demonstrated s...
The Erlotinib/Bevacizumab Combination in EGFR Mutation-Positive Advanced NSCLC: Is Progression-Free Survival without Overall Survival Benefit Enough? (BMIC-043)
Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva) with bevacizuma...
Small Trial Shows Big Risks of Giving First Line Pembrolizumab to EGFR Mutation-Positive Patients, Even with High Tumor PD-L1 Expression (BMIC-042)
Dr. Jack West summarizes a small trial from UCLA that tests the utility of giving first line immunotherapy to EGFR mutation-positive patients with hig...
IMpower131: What is the Role for the Carbo/Nab-Paclitaxel/Atezolizumab Combination for Advanced Squamous NSCLC? (BMIC-041)
Dr. Jack West summarizes key data from the IMpower131 trial of patients with advanced squamous NSCLC & examines whether the carboplatin/nab-paclitaxel...
Is Nivo/Ipi the Treatment of Choice for Patients with Advanced NSCLC, Tumor PD-L1 Under 1%, & High TMB? New Data from CheckMate 227 (BMIC-040)
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that suggests potential utility of the nivol...
KEYNOTE-407: Practice-Changing Positive Trial for Advanced Squamous NSCLC (BMIC-039)
Dr. Jack West reviews KEYNOTE-407, first line chemo/immunotherapy with pembrolizumab vs. chemo alone in advanced squamous NSCLC, which demonstrated a...
KEYNOTE-042: Should Pembrolizumab Replace Chemo for a Broader Population of Patients with Advanced NSCLC? (BMIC-038)
Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting key findings from the presentation in the...
My Top 5 ASCO 2018 Abstracts in Stage I-III NSCLC, Small Cell Lung Cancer, & Mesothelioma (BMIC-037)
Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and mesothelioma at ASCO 2018, explaining...
My Top 5 ASCO 2018 Abstracts in Advanced NSCLC (BMIC-036)
Dr. Jack West reviews his top 5 abstracts in the advanced NSCLC track at ASCO 2018, explaining why each is poised to change the landscape of patient c...